DaVita Inc. Reports Q4 Sales Increase, Shares Rise

DaVita Inc. (NYSE: DVA) reported higher fourth-quarter 2025 revenue on February 2, 2026, driven by strong patient volume and pricing improvements in its kidney care segment. The company posted sales of $3.32 billion, up 4.2% year-over-year, surpassing analyst estimates. Net income attributable to shareholders rose to $218 million, or $2.35 per share, compared to $192 million, or $2.01 per share, in the same period last year. Adjusted EBITDA reached $625 million, reflecting a 5.1% increase. CEO Javier Rodriguez cited operational efficiencies and strategic investments in value-based care as key contributors to the performance. The company also raised its full-year 2026 adjusted EBITDA guidance range.